2024-07-07 08:30:00 ET
Summary
- CRISPR Therapeutics AG investors have endured a challenging bear market decline.
- CRSP's buying momentum has waned as it struggles to stay above the $50 support level.
- Crispr's pipeline is mainly in the early stages, with Casgevy being the only commercially approved program.
- CRSP aims to expand its TAM and reach sustainable profitability over time.
- I argue why CRSP is close to an inflection point, suggesting buyers should consider capitalizing on its recent pessimism.
Crispr Stock: Casgevy-Linked FOMO Has Dissipated
CRISPR Therapeutics AG ( CRSP ) investors have endured a challenging two months as buying momentum on the biotech company's stock has waned. As a result, CRSP trades near lows last seen before Crispr received FDA approval for Casgevy in December 2023. Despite that, Seeking Alpha Quant still assigns CRSP a "B-" momentum grade , underscoring its resilience....
Read the full article on Seeking Alpha
For further details see:
Crispr Therapeutics: Beaten Down But Not Broken